Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review

[1]  P. Nathan,et al.  Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. , 2023, The Lancet. Oncology.

[2]  S. Wolden,et al.  Vital organ sparing with proton therapy for pediatric hodgkin lymphoma: Toxicity and outcomes in 50 patients. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Dalia R El-Afify,et al.  Omega 3 fatty acids can reduce early doxorubicin‐induced cardiotoxicity in children with acute lymphoblastic leukemia , 2021, Pediatric blood & cancer.

[4]  C. Weldon,et al.  Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study , 2021, Cancer.

[5]  G. Vassal,et al.  Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Ugrasena,et al.  Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study , 2021, Asian Pacific journal of cancer prevention : APJCP.

[7]  F. Zhou,et al.  Anthracycline Induced Cardiac Disorders in Childhood Acute Lymphoblastic Leukemia: A Single-Centre, Retrospective, Observational Study , 2021, Frontiers in Pharmacology.

[8]  M. Chan,et al.  Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population , 2021, Frontiers in Pediatrics.

[9]  G. Chagaluka,et al.  Early doxorubicin cardiotoxicity in Malawian children admitted to Queen Elizabeth Central Hospital, Malawi. , 2020 .

[10]  S. Shen,et al.  The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China , 2020, Pediatric hematology and oncology.

[11]  Adriana Linares Ballesteros,et al.  Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study , 2020, Colombia medica.

[12]  H. Grotenhuis,et al.  Cardiac Disease in Childhood Cancer Survivors , 2020, JACC. CardioOncology.

[13]  Ronald A. Li,et al.  Circulating high-sensitivity troponin T and microRNAs as markers of myocardial damage during childhood leukaemia treatment , 2020, Pediatric Research.

[14]  C. D. de Korte,et al.  Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines. , 2020, The American journal of cardiology.

[15]  M. Khalfallah,et al.  Right ventricular 2D speckle-tracking echocardiography in children with osteosarcoma under chemotherapy , 2019, The Egyptian Heart Journal.

[16]  C. Ross,et al.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment , 2019, Cardiovascular research.

[17]  M. H. van den Berg,et al.  Risk and Temporal Changes of Heart Failure Among 5‐Year Childhood Cancer Survivors: a DCOG‐LATER Study , 2018, Journal of the American Heart Association.

[18]  A. Hagag,et al.  Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia. , 2018, Infectious disorders drug targets.

[19]  Jennifer E Liu,et al.  Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy. , 2018, JACC. Cardiovascular imaging.

[20]  Vineeta Gupta,et al.  Role of ACE inhibitors in anthracycline‐induced cardiotoxicity: A randomized, double‐blind, placebo‐controlled trial , 2018, Pediatric blood & cancer.

[21]  A. Borkhardt,et al.  Daunorubicin during delayed intensification decreases the incidence of infectious complications – a randomized comparison in trial CoALL 08-09 , 2018, Leukemia & lymphoma.

[22]  A. Gézsi,et al.  Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma , 2018, BMC Cancer.

[23]  B. Printz,et al.  Utility of Echocardiography as Screening for Late-onset Anthracycline-induced Cardiotoxicity in Pediatric Cancer Survivors: Observations from the First Decade After End of Therapy , 2018, Journal of pediatric hematology/oncology.

[24]  Huimin Hu,et al.  Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor , 2018, Chinese medical journal.

[25]  P. Nathan,et al.  Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Huimin Hu,et al.  Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors , 2018, Pediatric hematology and oncology.

[27]  S. Lipshultz,et al.  Chemotherapy-induced cardiotoxicity in children , 2017, Expert opinion on drug metabolism & toxicology.

[28]  A. Kamel,et al.  Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma. , 2017, Journal of the Egyptian National Cancer Institute.

[29]  N. André,et al.  Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a “European Pediatric Oncology Off-patents Medicines Consortium” trial , 2016, Cancer Chemotherapy and Pharmacology.

[30]  S. Lipshultz,et al.  Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Shalaby,et al.  Early Ventricular Dysfunction After Anthracycline Chemotherapy in Children , 2016, Pediatric Cardiology.

[32]  James D. Thomas,et al.  Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. , 2015, Journal of the American College of Cardiology.

[33]  P. Nathan,et al.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. , 2015, The Lancet. Oncology.

[34]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[35]  C. Kuehni,et al.  A New Method to Facilitate Valid and Consistent Grading Cardiac Events in Childhood Cancer Survivors Using Medical Records , 2014, PloS one.

[36]  A. S. Shaikh,et al.  Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan , 2013, BMJ Open.

[37]  Ton Feuth,et al.  Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. , 2013, European heart journal cardiovascular Imaging.

[38]  G. Sandor,et al.  Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: A longitudinal study , 2013, Pediatric blood & cancer.

[39]  J. Oh,et al.  Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients , 2012, Journal of chemotherapy.

[40]  M. Gönen,et al.  Reliability of adverse symptom event reporting by clinicians , 2012, Quality of Life Research.

[41]  E. Chow,et al.  Strategies to Prevent Anthracycline-Related Congestive Heart Failure in Survivors of Childhood Cancer , 2012, Cardiology research and practice.

[42]  N. El-Shitany,et al.  Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. , 2012, Journal of cardiac failure.

[43]  Mohammed A. Al-Biltagi,et al.  Strain Echocardiography in Early Detection of Doxorubicin-Induced Left Ventricular Dysfunction in Children with Acute Lymphoblastic Leukemia , 2012, ISRN pediatrics.

[44]  S. Guler,et al.  The Value of Echocardiography Versus Cardiac Troponin I levels in the Early Detection of Anthracycline Cardiotoxicity in Childhood Acute Leukemia: Prospective Evaluation of a 7-Year-Long Clinical Follow-up , 2011, Pediatric hematology and oncology.

[45]  G. Levitt,et al.  Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United Kingdom , 2011, Pediatric blood & cancer.

[46]  S. Lipshultz,et al.  Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines , 2011, Cardiology research and practice.

[47]  S. Lipshultz,et al.  Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer , 2011, Pediatric Cardiology.

[48]  H. Shin,et al.  Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors , 2010, Journal of Korean medical science.

[49]  A. Heusch,et al.  Present Risk of Anthracycline or Radiation-induced Cardiac Sequelae Following Therapy of Malignancies in Children and Adolescents , 2009, Klinische Padiatrie.

[50]  J. Steinberger,et al.  Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group , 2008, Pediatrics.

[51]  D. Reinhardt,et al.  Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML , 2007, Pediatric blood & cancer.

[52]  S. Lipshultz,et al.  Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management , 2007, Expert opinion on pharmacotherapy.

[53]  Y. Genç,et al.  Early prediction of anthracycline induced cardiotoxicity , 2007, Acta paediatrica.

[54]  H. Caron,et al.  Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. , 2006, European journal of cancer.

[55]  H. Caron,et al.  Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. , 2006, European journal of cancer.

[56]  D. Green,et al.  Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  P. Voûte,et al.  Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  P. Voûte,et al.  Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  D. Fukumi,et al.  Longitudinal evaluation of anthracycline cardiotoxicity by signal‐averaged electrocardiography in children with cancer , 2002, Pediatrics international : official journal of the Japan Pediatric Society.

[60]  R. D. de Winter,et al.  Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. , 2002, European journal of cancer.

[61]  K. Schulz,et al.  Cohort studies: marching towards outcomes , 2002, The Lancet.

[62]  E Glattre,et al.  Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  J. Potter,et al.  Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  N. Jaffe,et al.  Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. , 2001, Oncology reports.

[65]  L. Brown,et al.  Interval Estimation for a Binomial Proportion , 2001 .

[66]  J. Furui,et al.  Sequential evaluation of left ventricular myocardial performance in children after anthracycline therapy. , 2000, The American journal of cardiology.

[67]  S. Lipshultz,et al.  Epidemiology of anthracycline cardiotoxicity in children and adults. , 1998, Seminars in oncology.

[68]  S. Lipshultz.  Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[70]  P Tugwell,et al.  Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. , 1994, JAMA.

[71]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: V. How to Use an Article About Prognosis , 1994 .

[72]  S. Colan,et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[73]  H. Grotenhuis,et al.  Cardiac Disease in Childhood Cancer Survivors Risk Prediction, Prevention, and Surveillance: JACC CardioOncology State-of-the-Art Review , 2020 .

[74]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[75]  T. Alonzo,et al.  Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  D. Cutter,et al.  University of Birmingham Population-based long-term cardiac-specific mortality among 34,489 five-year survivors of childhood cancer in Great Britain , 2017 .

[77]  A. Petrilli,et al.  Left ventricular systolic function assessed by echocardiography in children and adolescents with osteosarcoma treated with doxorubicin alone or in combination with dexrazoxane. , 2006, Arquivos brasileiros de cardiologia.

[78]  W. Stöhr,et al.  Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS) , 2005, Journal of Cancer Research and Clinical Oncology.

[79]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[80]  N. Dubrawsky.  Cancer statistics , 2022 .